ABSTRACT We studied the differential response to inhaled salbutamol and ipratropium of 29 asthmatic patients, 18 intrinsic, 11 extrinsic, using peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC). Thirty minutes after a theoretically maximally bronchodilating dose of salbutamol (400 ,g) or ipratropium (80 ug), second doses frequently caused further bronchodilatation. We suspect that second doses may reach bronchi untouched by the first inhalation. Analysis of variance showed a powerful intrinsic versus extrinsic effect, and there were clearly differences between patients in their response to treatment (patient versus drug interaction) but these differences were not removed by dividing the patients into intrinsic and extrinsic groups. Results for the group as a whole favoured salbutamol, but examination of individual results by a pattern-recognition technique showed ipratropium equally effective in eight patients and more effective in three. All patients with a definite predominant salbutamol response were less than 40 years old. The response to salbutamol declined significantly with age, whereas that to ipratropium did not. In general in patients aged less than 40 years salbutamol is the drug of choice. With advancing age, and the apparent decline of fl-adrenergic responsiveness, the initially comparatively small response to ipratropium becomes relatively more important and may predominate. In older patients ipratropium, or continued therapy with both drugs, may be preferable.
The role of the vagus nerve in clinical asthma presents some controversy. Thus in dogs, allergic asthma has been found to be mediated reflexly, with both afferent and efferent limbs in the vagus nerve.1 In patients a role for the vagus nerve has been suggested not only in allergic reactions, but when airway epithelium is eroded by infection,2 and irritant gases may have a similar action.3 Szentivanyi4 on the other hand has postulated a primary defect in the,8-adrenergic system. Parker and colleagues 7 have shown alterations in cyclic AMP metabolism at the cellular level in human bronchial asthma. An initial claim that atropine could completely inhibit antigen-induced bronchoconstriction8 has not been confirmed.9 10 It seems reasonable therefore to examine the differential response to an atropine-like drug (ipratropium) and a fl-adrenoceptor agonist (salbutamol) in asthmatic patients. If patients responding better to one or the other drug could be identified and classified, this would be relevant to both the aetiology of asthma and its rational treatment.
Methods
Twenty-nine patients who had been shown to increase their FEV1 by at least 15% in response to isoprenaline inhalation were chosen for this study (table 1) . Each patient was assessed before the study by a medical history including a modified MRC questionnaire on respiratory symptoms, physical examination, chest radiograph, and electrocardiogram. Eleven patients were extrinsic asthmatics, defined as having labile airways obstruction ( > 15 % response in FEV1 to a bronchodilator inhalation on at least three occasions), and positive skin-prick test reactions to at least two allergens. Eighteen were intrinsic asthmatics, with a bronchodilator 2D) to the extent that there are no significant differences between the response lines. Although in all examples given the final increase in FEV1 was slightly less when ipratropium was given first, this difference was never statistically significant.
Since it appeared (fig 2) that there might be groups of patients responding differently to the drugs, we proceeded to an analysis of variance. Table 3 shows 25 and 75 % of the total response was from salbutamol whatever the order (three patients); grade IV-> 75% of TR from either ipratropium or salbutamol whichever was given first (five patients); grade V-> 75% of TR from ipratropium if given first, % if given second (mirror image of grade II) (three patients); grade VI-> 75 % total response from ipratropium, whatever the order (mirror image of grade I) (no patients).
For classes I and II, salbutamol is evidently the preferred drug, and for classes V and VI ipratropium would be the preferable single agent.
From the numbers in the right-hand column of fig 3, a frequency distribution could be obtained, most patients falling in grades I and II. Contingency tables were constructed to analyse the differences between distributions of various possible discriminating categories using the chi-square test. The only significant discriminatory category we could find was the division of patients into age groups above and below 40 years, when all patients in the younger group fell into grade I or II (p < 0.01, fig 4) . Neither systolic nor diastolic blood pressure showed significant change.
PROGRESSIVE CHANGES WITH AGE
Inspection of the results suggested that on the whole older patients had smaller changes after bronchodilatation, and that this was more marked for salbutamol than ipratropium. This was confirmed by regressing the bronchodilator effect on FEV1 (AFEV1 in litres) against age in years, when there is a significant negative correlation for salbutamol that taking the total response as 100 %, the difficulties of interpatient differences in baseline respiratory function and magnitude of response are avoided. Our results suggest that the differential response to ipratropium and salbutamol is age-related, although it must be noted that age and intrinsicextrinsic status are closely linked. The response was not related to the duration of asthmatic symptoms, nor to any systematic difference in treatment, and the older patients had in fact asthma of shorter duration (table 1) . We found a rather weak but significant negative correlation between the bronchodilator effect of salbutamol and increasing age, but no such correlation for ipratropium. This suggests that whereas in young patients the fl-agonist effect is large compared with the atropine-like effect of ipratropium, the,f-agonist effect declines with age, while the atropine-like effect remains constant, and becomes proportionately more important with age until in some patients ipratropium may be more effective than salbutamol. This might be the result of a progressive decrease of fl-receptor function or a progressive loss of fl-receptors with age as is thought to occur with human cardiac22 and neural tissue. 23 The apparently good response to ipratropium in chronic bronchitis24-2 may simply reflect the fact that published series of such patients tend to be older than published series of asthmatics. Our asthmatic patients with chronic cough and sputum showed no difference in distribution across grades I-V compared with patients without those symptoms.
The therapeutic implications are clear. In patients aged less than 40 years, salbutamol is the single drug of choice, though ipratropium may be used if a ,8-agonist is for some reason contraindicated. In patients over 40 ipratropium is comparatively increasingly effective, may be used rationally in addition to a fl-agonist, and is in some patients the single drug of choice. 
